SCHEMBL31460077

SCHEMBL31460077

COc1cc(C2CC2)c(C(=O)O)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
KDM4E B2RXH2 2/20 0.41
KDM4C Q9H3R0 2/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CAMKK1 Q8N5S9 1/20 0.39
CAMKK2 Q96RR4 1/20 0.39
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
PIN1 Q13526 1/20 0.38
PYGL P06737 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
PDE5A O76074 1/20 0.37
DRD5 P21918 1/20 0.37
MAPT P10636 1/20 0.37
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31459951 0.94 MAPK1 (0.45) MAPK1LMNAHTTRAB9AKDM4E
SCHEMBL31459857 0.81 LCK (0.51) KDM4ELCKFYNALDH1A1HPGD
SCHEMBL3423769 0.78 ALDH1A1 (0.55) MAPK1LMNAHTTRAB9AKDM4E
SCHEMBL17700509 0.78 HTT (0.55) MAPK1LMNAHTTRAB9AKDM4E
SCHEMBL15544129 0.77 SLC6A3 (0.39) NOTUMALDH1A1HPGDSCN9A
SCHEMBL24746185 0.76 NOTUM (0.38) KDM4ECAMKK2NOTUMMAPT
SCHEMBL18700941 0.74 HTT (0.55) MAPK1LMNAHTTRAB9AKDM4E
SCHEMBL17258826 0.73 HTR2A (0.44) DRD5HTR2A
SCHEMBL2476566 0.73 RAB9A (0.50) MAPK1LMNAHTTRAB9AKDM4E
SCHEMBL19554326 0.73 KDM4E (0.51) MAPK1LMNAHTTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 MAPK1 2362/4885LMNA 2194/4885HTT 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.